Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study)

Tomoko Ueda-Consolvo; Masaaki Ishida; Tomoko Nakamura; Shuichiro Yanagisawa; Kotaro Tsuboi; Taku Wakabayashi; Atsushi Hayashi; Ashish Sharma; Baruch D. Kuppermann; Anat Loewenstein; Francesco Bandello; Carl D. Regillo; Luke Nicholson; Clara Vazquez-Alfageme; Nilesh Kumar; Nikulaa Parachuri; Jay Sheth; Seemantini Ayachit; Chitaranjan Mishra; Debdulal Chakraborty; Alay Banker; Kourous A. Rezaei; Arshad M. Khanani; Peter K. Kaiser; Ramin Tadayoni; Frank G. Holz; Sobha Sivaprasad; David Sarraf; Giuseppe Querques; Şengül Özdek; Kodjikian Laurent; Alper Bilgic; Paolo Lanzetta; Caroline Baumal; Nancy Holekemp; Taiji Sakamoto; Adnan Tufail; Nicolas Yannuzzi; Giulia Corradetti; Assaf Hilely; David Boyer; Aleksandra Rachitskaya; Tunde Peto; Maximilian W.M. Wintergerst; Valentina Sarao; Barbara Parolini; Prithvi Mruthyunjaya; Quan Dong Nguyen; Diana V. DO; Pearse A. Keane; International Retina Biosimilar Study Group (Inter BIOS Group)*

doi:10.1038/s41433-024-03220-z

Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study)

Tomoko Ueda-Consolvo
, Masaaki Ishida
, Tomoko Nakamura
, Shuichiro Yanagisawa
, Kotaro Tsuboi
, Taku Wakabayashi
, Atsushi Hayashi
, Ashish Sharma^*
, Baruch D. Kuppermann
, Anat Loewenstein
, Francesco Bandello
, Carl D. Regillo
, Luke Nicholson
, Clara Vazquez-Alfageme
, Nilesh Kumar
, Nikulaa Parachuri
, Jay Sheth
, Seemantini Ayachit
, Chitaranjan Mishra
, Debdulal Chakraborty

Alay Banker, Kourous A. Rezaei, Arshad M. Khanani, Peter K. Kaiser, Ramin Tadayoni, Frank G. Holz, Sobha Sivaprasad, David Sarraf, Giuseppe Querques, Şengül Özdek, Kodjikian Laurent, Alper Bilgic, Paolo Lanzetta, Caroline Baumal, Nancy Holekemp, Taiji Sakamoto, Adnan Tufail, Nicolas Yannuzzi, Giulia Corradetti, Assaf Hilely, David Boyer, Aleksandra Rachitskaya, Tunde Peto, Maximilian W.M. Wintergerst, Valentina Sarao, Barbara Parolini, Prithvi Mruthyunjaya, Quan Dong Nguyen, Diana V. DO, Pearse A. Keane, International Retina Biosimilar Study Group (Inter BIOS Group)*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Anti-vascular endothelial growth factor (VEGF) injections are the mainstay of treatment for retinal vascular diseases. However, despite their efficacy, the cost of long term intravitreal injections poses a significant burden on patients and healthcare systems. Recently, ranibizumab biosimilar (ranibizumab BS1, Senju Pharmaceuticals Co Ltd) has become available in Japan [1]. Ranibizumab BS1 is expected to have equivalent efficacy to the originator ranibizumab (0.5 mg) (Lucentis, Genentech, USA) but costs approximately 50% less (85,535 yen/560 USD versus 166,698 yen/1090 USD at the time of approval) per injection. Here, we report the early clinical outcomes regarding safety and efficacy in patients receiving ranibizumab BS1 injections for various retinal diseases. This study is part of the initiative undertaken by the international retina biosimilar study group (Inter BIOS Group).

Original language	English
Journal	Eye (Basingstoke)
Early online date	23 Jul 2024
DOIs	https://doi.org/10.1038/s41433-024-03220-z
Publication status	Early online date - 23 Jul 2024

ASJC Scopus subject areas

Ophthalmology
Sensory Systems

Access to Document

10.1038/s41433-024-03220-zLicence: Unspecified

Cite this

Ueda-Consolvo, T., Ishida, M., Nakamura, T., Yanagisawa, S., Tsuboi, K., Wakabayashi, T., Hayashi, A., Sharma, A., Kuppermann, B. D., Loewenstein, A., Bandello, F., Regillo, C. D., Nicholson, L., Vazquez-Alfageme, C., Kumar, N., Parachuri, N., Sheth, J., Ayachit, S., Mishra, C., ... International Retina Biosimilar Study Group (Inter BIOS Group)* (2024). Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study). Eye (Basingstoke). Advance online publication. https://doi.org/10.1038/s41433-024-03220-z

@article{f9630bdbc2044654baefa98bd05449d7,

title = "Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study)",

abstract = "Anti-vascular endothelial growth factor (VEGF) injections are the mainstay of treatment for retinal vascular diseases. However, despite their efficacy, the cost of long term intravitreal injections poses a significant burden on patients and healthcare systems. Recently, ranibizumab biosimilar (ranibizumab BS1, Senju Pharmaceuticals Co Ltd) has become available in Japan [1]. Ranibizumab BS1 is expected to have equivalent efficacy to the originator ranibizumab (0.5 mg) (Lucentis, Genentech, USA) but costs approximately 50\% less (85,535 yen/560 USD versus 166,698 yen/1090 USD at the time of approval) per injection. Here, we report the early clinical outcomes regarding safety and efficacy in patients receiving ranibizumab BS1 injections for various retinal diseases. This study is part of the initiative undertaken by the international retina biosimilar study group (Inter BIOS Group).",

author = "Tomoko Ueda-Consolvo and Masaaki Ishida and Tomoko Nakamura and Shuichiro Yanagisawa and Kotaro Tsuboi and Taku Wakabayashi and Atsushi Hayashi and Ashish Sharma and Kuppermann, \{Baruch D.\} and Anat Loewenstein and Francesco Bandello and Regillo, \{Carl D.\} and Luke Nicholson and Clara Vazquez-Alfageme and Nilesh Kumar and Nikulaa Parachuri and Jay Sheth and Seemantini Ayachit and Chitaranjan Mishra and Debdulal Chakraborty and Alay Banker and Rezaei, \{Kourous A.\} and Khanani, \{Arshad M.\} and Kaiser, \{Peter K.\} and Ramin Tadayoni and Holz, \{Frank G.\} and Sobha Sivaprasad and David Sarraf and Giuseppe Querques and {\c S}eng{\"u}l {\"O}zdek and Kodjikian Laurent and Alper Bilgic and Paolo Lanzetta and Caroline Baumal and Nancy Holekemp and Taiji Sakamoto and Adnan Tufail and Nicolas Yannuzzi and Giulia Corradetti and Assaf Hilely and David Boyer and Aleksandra Rachitskaya and Tunde Peto and Wintergerst, \{Maximilian W.M.\} and Valentina Sarao and Barbara Parolini and Prithvi Mruthyunjaya and Nguyen, \{Quan Dong\} and DO, \{Diana V.\} and Keane, \{Pearse A.\} and \{International Retina Biosimilar Study Group (Inter BIOS Group)*\}",

year = "2024",

month = jul,

day = "23",

doi = "10.1038/s41433-024-03220-z",

language = "English",

journal = "Eye (Basingstoke)",

issn = "0950-222X",

publisher = "Springer Nature",

}

Ueda-Consolvo, T, Ishida, M, Nakamura, T, Yanagisawa, S, Tsuboi, K, Wakabayashi, T, Hayashi, A, Sharma, A, Kuppermann, BD, Loewenstein, A, Bandello, F, Regillo, CD, Nicholson, L, Vazquez-Alfageme, C, Kumar, N, Parachuri, N, Sheth, J, Ayachit, S, Mishra, C, Chakraborty, D, Banker, A, Rezaei, KA, Khanani, AM, Kaiser, PK, Tadayoni, R, Holz, FG, Sivaprasad, S, Sarraf, D, Querques, G, Özdek, Ş, Laurent, K, Bilgic, A, Lanzetta, P, Baumal, C, Holekemp, N, Sakamoto, T, Tufail, A, Yannuzzi, N, Corradetti, G, Hilely, A, Boyer, D, Rachitskaya, A, Peto, T, Wintergerst, MWM, Sarao, V, Parolini, B, Mruthyunjaya, P, Nguyen, QD, DO, DV, Keane, PA & International Retina Biosimilar Study Group (Inter BIOS Group)* 2024, 'Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study)', Eye (Basingstoke). https://doi.org/10.1038/s41433-024-03220-z

TY - JOUR

T1 - Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study)

AU - Ueda-Consolvo, Tomoko

AU - Ishida, Masaaki

AU - Nakamura, Tomoko

AU - Yanagisawa, Shuichiro

AU - Tsuboi, Kotaro

AU - Wakabayashi, Taku

AU - Hayashi, Atsushi

AU - Sharma, Ashish

AU - Kuppermann, Baruch D.

AU - Loewenstein, Anat

AU - Bandello, Francesco

AU - Regillo, Carl D.

AU - Nicholson, Luke

AU - Vazquez-Alfageme, Clara

AU - Kumar, Nilesh

AU - Parachuri, Nikulaa

AU - Sheth, Jay

AU - Ayachit, Seemantini

AU - Mishra, Chitaranjan

AU - Chakraborty, Debdulal

AU - Banker, Alay

AU - Rezaei, Kourous A.

AU - Khanani, Arshad M.

AU - Kaiser, Peter K.

AU - Tadayoni, Ramin

AU - Holz, Frank G.

AU - Sivaprasad, Sobha

AU - Sarraf, David

AU - Querques, Giuseppe

AU - Özdek, Şengül

AU - Laurent, Kodjikian

AU - Bilgic, Alper

AU - Lanzetta, Paolo

AU - Baumal, Caroline

AU - Holekemp, Nancy

AU - Sakamoto, Taiji

AU - Tufail, Adnan

AU - Yannuzzi, Nicolas

AU - Corradetti, Giulia

AU - Hilely, Assaf

AU - Boyer, David

AU - Rachitskaya, Aleksandra

AU - Peto, Tunde

AU - Wintergerst, Maximilian W.M.

AU - Sarao, Valentina

AU - Parolini, Barbara

AU - Mruthyunjaya, Prithvi

AU - Nguyen, Quan Dong

AU - DO, Diana V.

AU - Keane, Pearse A.

AU - International Retina Biosimilar Study Group (Inter BIOS Group)

PY - 2024/7/23

Y1 - 2024/7/23

N2 - Anti-vascular endothelial growth factor (VEGF) injections are the mainstay of treatment for retinal vascular diseases. However, despite their efficacy, the cost of long term intravitreal injections poses a significant burden on patients and healthcare systems. Recently, ranibizumab biosimilar (ranibizumab BS1, Senju Pharmaceuticals Co Ltd) has become available in Japan [1]. Ranibizumab BS1 is expected to have equivalent efficacy to the originator ranibizumab (0.5 mg) (Lucentis, Genentech, USA) but costs approximately 50% less (85,535 yen/560 USD versus 166,698 yen/1090 USD at the time of approval) per injection. Here, we report the early clinical outcomes regarding safety and efficacy in patients receiving ranibizumab BS1 injections for various retinal diseases. This study is part of the initiative undertaken by the international retina biosimilar study group (Inter BIOS Group).

AB - Anti-vascular endothelial growth factor (VEGF) injections are the mainstay of treatment for retinal vascular diseases. However, despite their efficacy, the cost of long term intravitreal injections poses a significant burden on patients and healthcare systems. Recently, ranibizumab biosimilar (ranibizumab BS1, Senju Pharmaceuticals Co Ltd) has become available in Japan [1]. Ranibizumab BS1 is expected to have equivalent efficacy to the originator ranibizumab (0.5 mg) (Lucentis, Genentech, USA) but costs approximately 50% less (85,535 yen/560 USD versus 166,698 yen/1090 USD at the time of approval) per injection. Here, we report the early clinical outcomes regarding safety and efficacy in patients receiving ranibizumab BS1 injections for various retinal diseases. This study is part of the initiative undertaken by the international retina biosimilar study group (Inter BIOS Group).

U2 - 10.1038/s41433-024-03220-z

DO - 10.1038/s41433-024-03220-z

M3 - Article

C2 - 39043816

AN - SCOPUS:85199612115

SN - 0950-222X

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

ER -

Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study)

Abstract

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this